X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (38) 38
oncology (35) 35
index medicus (34) 34
male (23) 23
female (22) 22
middle aged (22) 22
aged (21) 21
adult (19) 19
cancer (17) 17
pancreatic cancer (14) 14
aged, 80 and over (12) 12
chemotherapy (12) 12
treatment outcome (12) 12
antineoplastic agents - therapeutic use (11) 11
mutation (11) 11
tumors (11) 11
care and treatment (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
gemcitabine (8) 8
prognosis (8) 8
survival (8) 8
analysis (7) 7
neoplasms - drug therapy (7) 7
neoplasms - genetics (7) 7
patients (7) 7
research (7) 7
cell lung-cancer (6) 6
metastases (6) 6
metastasis (6) 6
molecular targeted therapy (6) 6
neoplasm metastasis (6) 6
tor serine-threonine kinases - antagonists & inhibitors (6) 6
animals (5) 5
class i phosphatidylinositol 3-kinases (5) 5
colorectal cancer (5) 5
colorectal-cancer (5) 5
inhibitor (5) 5
medicine & public health (5) 5
mice (5) 5
phosphatidylinositol 3-kinases - genetics (5) 5
review (5) 5
solid tumors (5) 5
surgery (5) 5
therapy (5) 5
adenocarcinoma (4) 4
adjuvant chemotherapy (4) 4
adolescent (4) 4
article (4) 4
cancer patients (4) 4
carcinoma (4) 4
clinical trials (4) 4
deoxycytidine - analogs & derivatives (4) 4
expression (4) 4
gene (4) 4
medicine, research & experimental (4) 4
oncology trials (4) 4
pancreatic neoplasms - drug therapy (4) 4
pancreatic neoplasms - genetics (4) 4
pancreatic neoplasms - pathology (4) 4
patient outcomes (4) 4
phase i (4) 4
phosphatidylinositol 3-kinases - antagonists & inhibitors (4) 4
protein kinase inhibitors - therapeutic use (4) 4
proto-oncogene proteins - genetics (4) 4
proto-oncogene proteins b-raf - genetics (4) 4
proto-oncogene proteins p21 (4) 4
ras proteins - genetics (4) 4
retrospective studies (4) 4
xenograft model antitumor assays (4) 4
xenografts (4) 4
young adult (4) 4
1506 (3) 3
abridged index medicus (3) 3
antibodies (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antitumor activity (3) 3
benefits (3) 3
bevacizumab (3) 3
biology (3) 3
cancer therapies (3) 3
clinical trials, phase i as topic (3) 3
colorectal carcinoma (3) 3
diagnosis (3) 3
diarrhea (3) 3
disease-free survival (3) 3
dna sequencing (3) 3
double-blind (3) 3
ductal adenocarcinoma (3) 3
efficacy (3) 3
esophageal cancer (3) 3
gefitinib (3) 3
head and neck neoplasms - pathology (3) 3
immunotherapy (3) 3
inhibition (3) 3
kinases (3) 3
lung cancer (3) 3
lung neoplasms - drug therapy (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Clinical Oncology, ISSN 1759-4774, 06/2015, Volume 12, Issue 6, pp. 319 - 334
Journal Article
Cancer, ISSN 0008-543X, 10/2017, Volume 123, Issue 19, pp. 3816 - 3824
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 11/2019
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 7, p. e22769
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 04/2019, Volume 103, Issue 5, pp. E31 - E32
Journal Article
International Journal of Radiation OncologyBiologyPhysics, ISSN 0360-3016, 04/2019, Volume 103, Issue 5, pp. E31 - E32
Journal Article
Cancer Research, ISSN 0008-5472, 07/2015, Volume 75, Issue 13 Supplement, pp. B93 - B93
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4_suppl, pp. 97 - 97
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 419 - 419
Journal Article
Cancer, ISSN 0008-543X, 03/2012, Volume 118, Issue 5, pp. 1422 - 1428
BACKGROUND: The authors validated the Royal Marsden Hospital (RMH) prognostic score in patients with advanced lung, pancreatic, and head and neck cancers who... 
phase 1 trials | lung cancer | prognosis score | pancreatic cancer | head and neck cancer | SURVIVAL | ONCOLOGY TRIALS | RISKS | CONTEXT | TUMORS | INHIBITION | ONCOLOGY | EXPERIENCE | BENEFITS | Adenocarcinoma - pathology | Prognosis | Adenocarcinoma of Lung | Lung Neoplasms - mortality | Pancreatic Neoplasms - diagnosis | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Carcinoma - mortality | Lung Neoplasms - pathology | Male | Carcinoma, Squamous Cell - diagnosis | Neoplasm Metastasis | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Squamous Cell - mortality | Aged, 80 and over | Clinical Trials, Phase I as Topic - methods | Adult | Female | Pancreatic Neoplasms - mortality | Retrospective Studies | Carcinoma - pathology | Pancreatic Neoplasms - pathology | Head and Neck Neoplasms - therapy | Carcinoma, Squamous Cell - therapy | Carcinoma - diagnosis | Treatment Outcome | Lung Neoplasms - therapy | Cancer Care Facilities | Head and Neck Neoplasms - pathology | Adenocarcinoma - diagnosis | Adenocarcinoma - therapy | Texas | Carcinoma - therapy | Head and Neck Neoplasms - diagnosis | Aged | Head and Neck Neoplasms - mortality | Lung Neoplasms - diagnosis | Research Design | Adenocarcinoma - mortality | Pancreatic Neoplasms - therapy | Care and treatment | Pancreatic cancer | Patient outcomes | Outcome and process assessment (Health Care) | Head and neck cancer | Methods | Cancer
Journal Article
Cancer, ISSN 0008-543X, 07/2014, Volume 120, Issue 14, pp. 2164 - 2173
Journal Article